Idenix Pharmaceuticals LLC
(NASDAQ : IDIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.04%172.250.7%$1088.53m
PFEPfizer Inc. -0.02%42.780.9%$1062.98m
AZNAstraZeneca Plc -0.69%57.241.0%$983.21m
MRKMerck & Co., Inc. -0.13%76.830.7%$651.89m
ABBVAbbVie, Inc. -2.22%116.231.9%$651.72m
BMYBristol-Myers Squibb Co. -0.34%67.921.0%$580.36m
LLYEli Lilly & Co. -0.80%243.361.1%$577.91m
NRXPNRX Pharmaceuticals, Inc. 0.20%15.180.0%$167.78m
NVSNovartis AG 0.25%92.420.2%$154.78m
GSKGlaxoSmithKline Plc 0.13%40.150.2%$154.55m
RGENRepligen Corp. 1.95%245.706.8%$95.53m
VTRSViatris, Inc. -1.54%14.070.0%$86.29m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.06%126.060.0%$85.37m
NVONovo Nordisk A/S 1.32%92.580.1%$81.36m
RPRXRoyalty Pharma Plc -0.13%38.200.2%$73.90m

Company Profile

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).